Yu Shen, PhD.
Department of Biostatistics, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Oestmann Family Foundation Chair for Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Adjunct Member, University Graduate Programs, Texas A&M University, College Station, TX
Adjunct Professor, Department of Statistics, Rice University, Houston, TX
Adjunct Professor, Graduate School of Biomedical Sciences, The University of Texas, Houston, Houston, TX
Research Interests
- Data integration from real-world data and RCTs;
- Machine learning methods in survival data;
- Health economics research;
- Modeling cancer screening data
Education & Training
Postgraduate Training
| 1994-1995 | Postdoctoral Fellowship, Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington |
Experience & Service
Administrative Appointments/Responsibilities
co-lead Data Science Faculty Recruitment Committee, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present
Chair ad Interim, Biostatistics, University of Texas MD Anderson, 2020 - 2024
Other Professional Positions
LIDA Interest Group Program Chair, American Statistical Association, Alexandria, VA, 2017 - 2019
Member of the 2018 ENAR Program Committee, ENAR/The International Biometric Society, Washington, DC, 2017 - 2018
Member of Nominating Committee, ENAR/The International Biometric Society, Washington, DC, 2017
Site Visit Reviewer, NCI Board of Scientific Counselors for Biostatistics branch of NCI Intermural Program National Cancer Institute (NIH), Bethesda, MD, 2014
Secretary/Treasurer of Biometrics Section, American Statistical Association, Unknown, 2013 - 2014
Member of the Conference Program Committee, ICSA-KISS, Portland, OR, 2013 - 2014
Directors of ICSA board, International Chinese Statistical Association, Statesboro, GA, 2011 - 2013
Member, ENAR Program Committee 2011, Eastern North American Region, Reston, VA, 2009 - 2011
Representative for COPSS, ASA Elizabeth Scott Award Selection Committee, Washington, DC, 2000 - 2001
Extramural Institutional Committee Activities
Member, Faculty Recruitment Panel for Data Science, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Cancer Prevention Research Training Program Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Breast Cancer Moon Shot Internal Advisory Board (IAB), The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, Morgan Welch IBC Program Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, The Pathology & Laboratory Medicine Division Head Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Sponsor, Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program, The University of Texas MD Anderson Cancer Center, 2021
Member, HSR Department Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, 2018 - 2020
Member, Internal Advisory Board (IAB) for the SPORE in Breast Cancer, The University of Texas MD Anderson Cancer Center, 2016 - 2021
Member, M.D. Anderson Clinical Research Committee (CRC) 1, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, The Biostat Mentoring Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Executive Committee of Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, 2012 - 2018
Member, M.D. Anderson Clinical Research Committee (CRC) 2, The University of Texas MD Anderson Cancer Center, 2009 - 2011
Alternate Member, M. D. Anderson Cancer Center DSBM Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, Oversight Committee for Clinical Trial at MDACC, The University of Texas MD Anderson Cancer Center, 2007 - 2012
Member, Data Safety Monitoring Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2011
Member, Rice Joint Program Graduate Student Admission Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2009
Member, Faculty search committee for Epidemiology department, The University of Texas MD Anderson Cancer Center, 2007 - 2008
Chair, GSBS Biomathematics/Biostatistics Graduate Student Admission Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2009
Member, GSBS Biomathematics/Biostatistics Graduate Student Admission Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2009
Member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, 2003 - 2007
Member, Faculty Search Committee, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 2001 - 2019
Editorial Activities
Associate Editor, New England Journal of Statistics and Data Science, 2021 - Present
Associate Editor, Contemporary Clinical Trials Communications, Evise, 2015 - Present
Associate Editor, Lifetime Data Analysis, Springer, 2013 - Present
Associate Editor, Biometrics, 2006 - Present
Honors & Awards
| 2014 | Conversation with a Living Legend Professorship |
| 2007 | Elected Fellow, American Statistical Association |
| 2001 | Finalist, Julie and Ben Roger Award for Excellence |
| 1999 - 2001 | Cancer Research and Prevention Foundation award |
| 1994 - 1995 | NIH Post-Doctoral Training Fellowship, Prostate Cancer Screening Research Grants, University of Washington and Fred Hutchinson Cancer Research Center |
| 1988 - 1990 | Smith Fellowship in Mathematics, University of Notre Dame |
| 1988 - 1989 | Richard Sandy Prize in Mathematics, University of Notre Dame |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2022. Data Science: Learning from Clinical Trials, Real-World, and Simulated Data. Conference. The University of Texas M.D. Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS). Houston, TX, US.
- 2021. Data Science: Learning from Clinical Trial, Real-World, and Simulated Data. Conference. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2016. Network meta-analysis for adjuvant chemotherapy regimen for breast cancer. Conference. Informal Biostatistics Lunch Discussion. Houston, TX, US.
- 2012. Role and Promise of Observational Studies in Cancer Research. Conference. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2008. How evidence based research improves patient care: A leukemia study. Conference. Japan Medical Exchange Program, US.
- 2004. Adaptive sample size estimation in clinical trial designs. Conference. University of Texas M.D. Anderson Cancer Center,. Houston, TX, US.
- 2002. Estimation and its exact confidence interval following a hypothesis testing in the Self-designing trial. Invited. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2000. Early detection for breast cancer: How much can clinical breast cancer examinations add to mammograms?. Invited. Cancer Genetics Network Biostatistics Workshop. Houston, TX, US.
- 2000. Weighted two-sample test statistics for survival data in early detection trials. Invited. University of Texas M.D. Anderson Cancer Center. Houston, US.
- 1998. Statistical Methods for Estimating Quantities in Screening Programs. Invited. University of Texas M.D. Anderson Cancer Center. Houston, US.
- 1998. Sequential Design and Sample Size Selection in Clinical Trials. Invited. University of Texas M.D. Anderson Cancer Center. Houston, US.
- 1996. Parametric Likelihoods for times to multiple competing risk non-fatal events and death. Invited. University of Texas M.D. Anderson Cancer Center. Houston, US.
- 1995. Estimating Asymptotic Durations in Cancer: the AIDS Connection. Invited. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 1995. Estimation of Survival Distribution in Heterogeneous Samples and Assessment of Treatment Effects. Invited. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2024. Learning from multiple sources of data for personalized medicine. Invited. Annual Conference of Texas Statisticians 2024. Houston, Texas, US.
National Presentations
- 2026. Integrating Machine Learning into Survival Analysis through Distribution-free Conformal Prediction. Invited. Department of Biostatistics. Seattle, Washington, US.
- 2025. From Natural History to Mortality: Evaluating Screening Benefit. Invited. Early Detection Research Network (EDRN) Statistics Working Group, US.
- 2025. Unveiling survival insights: How detection methods and screening trial biases shape surrogate and mortality. Invited. Joint Statistical Meeting 2025. Nashville, TN, US.
- 2025. Synergizing multiple data sources to improve risk prediction. Invited. 2025 Lifetime Data Science Conference. New York, NY, US.
- 2025. Machine Learning in Statistical Inference with Survival Outcomes. Poster. SDSS 2025. Salt Lake City, UT, US.
- 2025. Evaluating Cancer Screening Programs: Statistical Methods and Microsimulation Insights. Invited. Seattle, WA, US.
- 2025. Integrating Multiple Data Sources: Enhancing Precision Medicine Risk Prediction. Invited. Madison, WI, US.
- 2024. Combining external aggregate information with primary data to improve statistical efficiency. Invited. JSM 2024. Portland, OR, US.
- 2024. Data Integration in Statistical Inference and Risk Prediction. Invited. Boston, MA, US.
- 2023. Modeling the COVID incubation period. Invited. Making an Impact in the Era of Data Science. Raleigh, NC, US.
- 2022. Leaning from Big Data: Simulated data and real-world data. Invited. Second Penn Conference on Big Data in Population Health Sciences. Philadelphia, PA, US.
- 2022. Evaluation of the nature history of dementia by combining incident and prevalent cohorts from the Nun study. Invited. JSM 2022. Washington DC, US.
- 2022. Data Science: Learning from Clinical Trial, Real-World, and Simulated Data. Invited. Data Science: Learning from Clinical Trial, Real-World, and Simulated Data, US.
- 2019. Density ratio model for analyzing length-biased data. Invited. 2019 Conference of Lifetime Data Science: Foundations and Frontiers (LiDS). Pittsburgh, PA, US.
- 2019. Challenge and promise of observational epidemiological studies in cancer medicine. Invited. Spring Central and Western Joint Sectional Meeting. Honolulu, HI, US.
- 2018. Analysis of Restricted Mean Survival Time for Length-Biased Data. Invited. SAM 2018 4th International Workshop on the Statistical Analysis of Multi-outcome Data. St. Louis, MO, US.
- 2018. Do Advances In Breast Cancer Treatment Render Screening Mammography Not Cost-Effective For Average-Risk Women. Invited. CHPAMS workshop. New Heaven, CT, US.
- 2018. Lead Round Table Discussion: Identifying the Non-identifiable: Non-progressive Cancers in Screened Populations. Invited. Eastern North American Region Spring Meeting 2018 (ENAR). Atlanta, GA, US.
- 2017. Estimation of cancer natural history from cancer screening trials. Conference. Western North American Region of The International Biometric Society. Santa Fe, NM, US.
- 2017. Do Advances in Breast Cancer Treatment Render Screening Mammography Not Cost-effective for Average-risk Women?”. Conference. ISPOR The Professional Society for Health Economics and Outcomes Research. Boston, MA, US.
- 2014. Challenges to Analyzing Survival Data Subject to Biased Sampling. Invited. Biometrics Section. Boston, MA, US.
- 2014. Efficient design for prospective observational studies. Invited. ICSA. Portland, OR, US.
- 2012. Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies. Invited. ICSA. Boston, MA, US.
- 2008. Semiparametric transformation models for length-biased data. Invited. Winemiller Conference: Survival Analysis and its application. Columbia, MO, US.
- 2007. Innovative Designs and Analysis in Clinical Trials - Fully Harnessing Patient Information accrued during a Trial. Invited. Joint Statistical Meeting. Salt Lake City, UT, US.
- 2006. Adaptive Designs in Clinical Trials. Invited. Joint Statistical Meeting. Seattle, WA, US.
- 2006. Adaptive Design and Analysis of Clinical Trials. Invited. ICSA Applied Statistics Symposium. Storrs, CT, US.
- 2005. Session - Innovative Designs in Clinical Trials. Invited. JSM 2005. Minneapolis, MN, US.
- 2005. Session - Adaptive Clinical Trial Designs. Invited. WNAR meeting. Fairbanks, AK, US.
- 2005. Session - Statistical Methods in Cancer Screening. Invited. ICSA Applied Statistics Symposium. Washington DC, US.
- 2005. Adaptive Clinical Trial design. Invited. IBC Adaptive Designs for Clinical Development workshop. Boston, MA, US.
- 2004. Adaptive design for clinical trials with censored survival data. Invited. ICSA Applied Statistics Symposium. San Diego, CA, US.
- 2003. Session - Competing Risks. Invited. WNAR Meeting. Golden, CO, US.
- 2003. Estimation of a parameter and its exact confidence interval following an adaptive design. Invited. International Biometric Society, Eastern North American Region. Tampa, FL, US.
- 2002. Sample size re-estimation for clinical trials with censored survival data. Invited. Joint Statistical Meeting. New York City, NY, US.
- 2002. Estimation of parameter and its exact confidence interval following a hypothesis testing in the self-designing trial. Invited. The Southern Regional Council on Statistics and the American Statistical Association Summer Research Conference in Statistics. Natchez, MS, US.
- 2002. Cancer Screening in New Millennium. Invited. Cancer Screening in New Millennium. Arlington, VA, US.
- 2001. Statistical inference for self-designing clinical trials. Invited. Joint Statistical Meeting. Atlanta, GA, US.
- 2001. Early detection for breast cancer: how much can clinical breast cancer examinations add to mammograms?. Invited. ENAR Spring Meeting. Charlotte, NC, US.
- 2000. Estimation of screening sensitivity and sojourn time distribution. Invited. International Biometric Society (ENAR) Spring Meeting. Chicago, IL, US.
- 1999. Sample-size re-estimate in clinical trials with a one-sided hypothesis. Invited. Joint Statistical Meeting. Baltimore, MD, US.
- 1998. Statistical methods for estimating quantities in screening programs. Invited. Conference for Carcinogenesis Modeling and Risk Assessment, Huntsman Cancer Institute. Park City, UT, US.
- 1998. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Conference. International Biometric Society (ENAR) Spring Meeting. Pittsburgh, PA, US.
- 1997. Parametric likelihoods for times to multiple competing risk non-fatal events and death. Conference. International Biometric Society (ENAR) Spring Meeting. Memphis, TN, US.
- 1995. Weighted Mean Survival Test Statistics: A Class of Distance Tests for Censored Survival Data. Conference. Joint Statistical Meetings. Orlando, FL, US.
International Presentations
- 2025. Integrating Machine Learning into Survival Analysis: Conformal Prediction. Invited. 2025 IMS International Conference on Statistics and Data Science (ICSDS), Seville, Spain. Calverton, US.
- 2025. Semiparametric Estimation of Longitudinal Medical Cost Trajectory. Invited. Joint Conference of the Italian and Eastern Mediterranean Regions of the International Biometric Society 2025. Salerno, IT.
- 2025. Transfer learning and uncertainty quantification in survival analysis. Invited. WNAR 2025. Whistler, CA.
- 2024. Integrating Multiple Sources of Data to Improve Statistical Inference. Invited. IMS China International Conference on Statistics and Probability. Yinchuan, CN.
- 2024. Accommodating Time-Varying Heterogeneity in Risk Estimation under the Cox Model: A Transfer Learning Approach. Invited. International Symposium on Nonparametric Statistics (ISNPS). Braga, PT.
- 2024. Synergizing multiple data sources: Enhancing precision medicine risk prediction. Invited. 2024 International Chinese Statistical Association (ICSA) Applied Statistics Symposium. Nashville, US.
- 2024. Data Integration in Statistical Inference. Invited. Barcelona, ES.
- 2024. A Holistic Review of Adaptive Designs and their Regulatory Alignment. Invited. Adaptive Designs and Multiple Testing Procedures Workshop. Ibiza, ES.
- 2023. Adaptive transfer learning approach to improving risk prediction with time-to-event data. Invited. 2023 IMS International Conference on Statistics and Data Science. Lisbon, PT.
Formal Peers
- 2006. Adaptive Clinical Trial Design. Invited. San Antonio, TX, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Cancer Center Support (CORE) Grant |
| Funding Source: | NATIONAL CANCER INSTITUTE |
| Role: | Co-PI |
| ID: | CA016672-50 |
| Date: | 2026 - 2031 |
| Title: | Advancing Transfer Learning Using Surrogates, Family History, and Prior Models |
| Funding Source: | National Institutes of Health |
| Role: | Co-I |
| ID: | R01CA316177 |
| Date: | 2026 - 2027 |
| Title: | Cancer Center Support (CORE) Grant |
| Funding Source: | National Cancer Institute |
| Role: | Key |
| ID: | 5P30CA016672-50 |
| Date: | 2026 - 2028 |
| Title: | Addressing Unmeasured Covariates in Source Cohorts with Transfer Learning for Survival Outcomes |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R21CA312466 |
| Date: | 2025 - 2027 |
| Title: | Addressing Unmeasured Covariates in Source Cohorts with Transfer Learning for Survival Outcomes |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| ID: | R21CA312466 |
| Date: | 2024 - 2029 |
| Title: | BC231271: Advancing our Understanding of Metastatic Breast Cancer through Development of a Comprehensive Research Platform |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | HT94252410991 |
| Date: | 2024 - 2028 |
| Title: | Advancing our Understanding of Metastatic Breast Cancer through Development of a Comprehensive Research Platform |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | HT94252410992 |
| Date: | 2023 - 2027 |
| Title: | Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA272806-01A1 |
| Date: | 2022 - 2027 |
| Title: | Clinical Validation Center for Early Detection of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2U01CA200468-06 |
| Date: | 2022 - 2027 |
| Title: | Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U54CA274371-01 |
| Date: | 2022 - 2027 |
| Title: | Statistical Methods for Integration of Multiple Data Sources toward Precision Cancer Medicine |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1R01CA269696-01 |
Selected Publications
Peer-Reviewed Articles
- Wang, Y, Shen, Y, Ning, J. Modeling disease-specific survival in observational studies with missing cause of death. Computational Statistics and Data Analysis 224, 2026. e-Pub 2026. PMID: 42281757.
- James P. Long, Abhishikta Roy, Ehsan Irajizad, Kim A Do, Yu Shen. Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials. Statistics in Medicine, 2026. e-Pub 2026. PMID: 42705867.
- Wang J, Ning J, Shaitelman SF, Lin HY, Bedrosian I, Shen Y. Radiotherapy de-escalation in breast cancer patients with pathologic complete response: An integrated analysis using real-world and simulated data. Int J Radiat Oncol Biol Phys, 2026. e-Pub 2026. PMID: 42173325.
- Qin, J, Piao, J, Ning, J, Shen, Y. Conformal predictive intervals in survival analysis. Biometrics 81(2), 2025. e-Pub 2025. PMID: 40417913.
- Dong W, Fujii T, Ning J, Iwase T, Qin J, Ueno NT, Shen Y. Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in HER2-negative Patients Using Shape Restricted Modeling. Scientific Reports 15(1), 2025. e-Pub 2025. PMID: 39955419.
- Chen Z, Shen Y, Qin J, Ning J. Likelihood Adaptively Incorporated External Aggregate Information with Uncertainty for Survival Data. Biometrics 80(4), 2024. e-Pub 2024. PMID: 39468742.
- Long, JP, Shen, Y. Detection method has independent prognostic significance in the PLCO lung screening trial. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 37591907.
- Pak D, Ning J, Kryscio RJ, Shen Y. Evaluation of the natural history of disease by combining incident and prevalent cohorts: application to the Nun Study. Lifetime Data Anal 29(4):1-17, 2023. e-Pub 2023. PMID: 37210470.
- Li Z, Shen Y, Ning J. Accommodating time-varying heterogeneity in risk estimation under the Cox model: a transfer learning approach. J Am Stat Assoc, 2023. e-Pub 2023. PMID: 38505403.
- Wang SK, Shen Y, Shih TYC, Xu Y, Li L. Statistical Modeling of Longitudinal Medical Cost Trajectory: Renal Cell Cancer Care Cost Analyse. Biostistics 24(2):244-261, 2023. e-Pub 2023. PMID: 34269395.
- Shen, Y, Ning, J, Lin, Y, Shaitelman, SF, Kuerer, HM, Bedrosian, I. Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial. Journal of Cancer 14(2):193-199, 2023. e-Pub 2023. PMID: 36741254.
- Zhu H, Lan Y, Ning J, Shen Y. Semiparametric copula-based regression modeling of semi-competing risks data. Communications in Statistics – Theory and Methods 51(22):7830–7845, 2022. e-Pub 2022.
- Qin, J, Deng, G, Ning, J, Yuan, A, Shen, Y. Estrogen receptor expression on breast cancer patients’ survival under shape-restricted cox regression model. Annals of Applied Statistics 15(3):1291-1307, 2021. e-Pub 2021. PMID: 34745408.
- Bofill Roig M, Shen Y, Gómez Melis G. Design of phase III trials with long-term survival outcomes based on short-term binary results. Stat Med 40(18):4122-4135, 2021. e-Pub 2021. PMID: 33942352.
- Etzioni R, Shen Y, Shih YT. Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective. J Natl Cancer Inst 113(6):660-661, 2021. e-Pub 2020. PMID: 33301010.
- Shih YT, Dong W, Xu Y, Etzioni R, Shen Y. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer: A Cost-Effectiveness Analysis. Ann Intern Med 174(5):602-612, 2021. e-Pub 2021. PMID: 33556275.
- Pak D, Liu J, Ning J, Gómez G, Shen Y. Analyzing left-truncated and right-censored infectious disease cohort data with interval-censored infection onset. Stat Med 40(2):287-298, 2021. e-Pub 2021. PMID: 33086432.
- Harun, N, Cai, B, Shen, Y. A Bayesian semiparametric method for analyzing length-biased data. Journal of Applied Statistics 48(6):977-992, 2021. e-Pub 2021. PMID: 35707737.
- Pak D, Langohr K, Ning J, Martinez JC, Melis LG, Shen Y. Age Associated Coronavirus Disease 2019 Incubation Period: Impact on Quarantine Policy. MDPI: Mathematics 8(9), 2020. e-Pub 2020.
- Lee CH, Zhou H, Ning J, Liu DD, Shen Y. CoxPhLb: An R Package for Analyzing Length-Biased Data under Cox Model. R Journal 12(1):118-130, 2020. e-Pub 2020. PMID: 33133648.
- Shih YT, Shen Y. Time to Consider a Personalized Approach to Incorporate Tomosynthesis into Routine Breast Cancer Screening. J Natl Cancer Inst 112(6):553-554, 2020. e-Pub 2020. PMID: 31503277.
- Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward W, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer 10(12):2635-2642, 2019. e-Pub 2019.
- Huang X, Liu L, Ning J, Li L, Shen Y. Estimation of the Distribution of Longitudinal Biomarker Trajectories Prior to Disease Progression. Stat Med 38(11):2030-2046, 2019. e-Pub 2019. PMID: 30614014.
- Lee CH, Ning J, Kryscio RJ, Shen Y. Analysis of combined incident and prevalent cohort data under a proportional mean residual life model. Stat Med 38(12):2103-2114, 2019. e-Pub 2019. PMID: 30680767.
- Piao J, Ning J, Shen Y. Semiparametric Model for Bivariate Survival Data Subject to Biased Sampling. J R Stat Soc Ser B 81(2):409-429, 2019. e-Pub 2019. PMID: 31435191.
- Shen Y, Dong W, Gulati R, Ryser MD, Etzioni R. Estimating the frequency of indolent breast cancer in screening trials. Stat Methods Med Res 28(4):1261-1271, 2019. e-Pub 2019. PMID: 29402176.
- Tina Shih YC, Dong W, Xu Y, Shen Y. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women from the American Cancer Society and US Preventive Services Task Force. Value Health 22(2):185-193, 2019. e-Pub 2019. PMID: 30711063.
- Lee CH, Ning J, Shen Y. Model diagnostics for the proportional hazards model with length-biased data. Lifetime Data Anal 25:79-96, 2019. e-Pub 2019. PMID: 29450809.
- Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: A network meta-analysis. Breast Cancer Res Treat 173(1):1-9, 2019. e-Pub 2019. PMID: 30242579.
- Mao H, Li L, Yang W, Shen Y. On the propensity score weighting analysis with survival outcome: estimands, estimation and inference. Stat Med 37(26):3745-63, 2018. e-Pub 2018. PMID: 29855060.
- Lee CH, Ning J, Shen Y. Analysis of Restricted Mean Survival Time for Length-Biased Data. Biometrics 74(2):575-583, 2018. e-Pub 2018. PMID: 28886217.
- Woodward WA, Ueno NT, Kuerer HM, Lucci A, Shen Y. Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. Breast 39:148-149, 2018. e-Pub 2018. PMID: 29729725.
- Li L, Wu CH, Ning J, Huang X, Tina Shih YC, Shen Y. Semiparametric Estimation of Longitudinal Medical Cost Trajectory. J Am Stat Assoc 113(522):582-592, 2018. e-Pub 2018. PMID: 30853736.
- Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer 123(14):2618-2625, 2017. e-Pub 2017. PMID: 28295213.
- Ning J, Hong C, Li L, Huang X, Shen Y. Estimating Treatment Effects in Observational Studies with Both Prevalent and Incident Cohorts. Can J Stat 45(2):202-219, 2017. e-Pub 2017. PMID: 29056817.
- Liu H, Shen Y, Ning J, Qin J. Sample size calculations for prevalent cohort designs. Stat Methods Med Res 26(1):280-291, 2017. e-Pub 2017. PMID: 25091809.
- Shen Y, Ning J, Qin J. Nonparametric and Semiparametric Regression Estimation for Length-biased Survival Data. Lifetime Data Anal 23(1):3-24, 2017. e-Pub 2017. PMID: 27086362.
- Liu H, Ning J, Qin J, Shen Y. Semiparametric Maximum Likelihood Inference for Truncated or Biased-Sampling Data. Stat Sinica 26(3):1087-1115, 2016. e-Pub 2016.
- Ning J, Peng S, Ueno N, Xu Y, Shih Y, Karuturi M, Giordano S, Shen Y. Has Racial Difference in Cause-Specific Death Improved in Older Patients with Late-Stage Breast Cancer?. Ann Oncol 26(10):2161-8, 2015. e-Pub 2015. PMID: 26223248.
- Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y. Cost-Effectiveness of Alternative Strategies for Integrating MRI into Breast Cancer Screening for Women at High Risk. Br J Cancer 111(8):1542-51, 2014. e-Pub 2014. PMID: 25137022.
- Ning J, Qin J, Shen Y. Score Estimating Equations from Embedded Likelihood Functions under Accelerated Failure Time Model. J Am Stat Assoc 109(508):1625-35, 2014. e-Pub 2014. PMID: 25663727.
- Shih YC, Xu Y, Dong W, Smieliauskas F, Giordano S, Shen Y. First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. Breast Cancer Res Treat 144(2):417-25, 2014. e-Pub 2014. PMID: 24557339.
- Ning J, Qin J, Shen Y. Semiparametric accelerated failure time model for length-biased data with application to dementia study. Stat Sin 24(1):313-333, 2014. e-Pub 2014. PMID: 24478570.
- Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T-cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1(4):229-34, 2013. e-Pub 2013. PMID: 24777852.
- Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic down-staging and long-term outcomes. Results from a retrospective study at the M. D. Anderson Cancer Center. Eur Urol 64(2):307-13, 2013. e-Pub 2013. PMID: 22564397.
- Ning J, Qin J, Asgharian M, Shen Y. Empirical likelihood-based confidence intervals for length-biased data. Stat Med 32(13):2278-2291, 2013. e-Pub 2013. PMID: 23027662.
- Cheng Y, Shen Y. An efficient sequential design of clinical trials. J Stat Plan Inference 143(2):283-295, 2013. e-Pub 2013. PMID: 23275685.
- Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637-43, 2012. e-Pub 2012. PMID: 22517269.
- Liu H, Qin J, Shen Y. Imputation for semiparametric transformation models with biased sampling data. Lifetime Data Anal 18(4):470-503, 2012. e-Pub 2012. PMID: 22903245.
- Shen Y, Ning J, Qin J. Likelihood approaches for invariant density ratio model with biased-sampling data. Biometrika 99(2):363-378, 2012. e-Pub 2012. PMID: 23843663.
- Ning J, Qin J, Shen Y. Buckley-James type Estimator with Right-censored and Length-biased Data. Biometrics 67(4):1369-78, 2011. e-Pub 2011. PMID: 21385160.
- Qin J, Ning J, Liu H, Shen Y. Maximum likelihood estimations and EM algorithms with length-biased data. J Am Stat Assoc 106(496):1434-49, 2011. e-Pub 2011. PMID: 22323840.
- Ahern CH, Cheng Y, Shen Y. Risk-specific optimal cancer screening schedules: an application to breast cancer early detection. Stat Biosci 3(2):169-186, 2011. e-Pub 2011. PMID: 22162743.
- Ning J, Qin J, Shen Y. Nonparametric tests for right-censored data with biased sampling. J R Stat Soc Ser B 72(5):609-630, 2010. e-Pub 2010. PMID: 21031144.
- Qin J, Shen Y. Statistical Methods for Analyzing Right-censored Length-biased Data under Cox Model. Biometrics 66(2):382-392, 2010. e-Pub 2010. PMID: 19522872.
- Liu H, Shen Y. A Semiparametric Regression Cure Model for Interval-Censored Data. J Am Stat Assoc 104(487):1168-1178, 2009. e-Pub 2009. PMID: 20354594.
- Shen Y, Ning J, Qin J. Analyzing Length-biased Data with Semiparametric Transformation and Accelerated Failure Time Models. J Am Stat Assoc 104(487):1192-1202, 2009. e-Pub 2009. PMID: 21057599.
- Ahern CH, Shen Y. Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev 18(3):718-725, 2009. e-Pub 2009. PMID: 19258473.
- Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer 115(10):2041-2051, 2009. e-Pub 2009. PMID: 19288569.
- Shen Y, Costantino JP, Qin J. Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. J Natl Cancer Inst 100(20):1448-53, 2008. e-Pub 2008. PMID: 18840821.
- Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17(5):1096-103, 2008. e-Pub 2008. PMID: 18483331.
- Shen Y, Qin J, Costantino JP. Inference of Tamoxifen's Effects on Prevention of Breast Cancer from a Randomized Controlled Trial. J Am Stat Assoc 102(480):1235-1244, 2007. e-Pub 2007. PMID: 19662105.
- Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?. Breast Cancer Res Treat 102(3):347-356, 2007. e-Pub 2007. PMID: 17028980.
- Shen Y, Cheng Y. Adaptive Design: Estimation and Inference with Censored Data in a Semiparametric Model. Biostatistics 8:306-322, 2007. e-Pub 2007. PMID: 16787996.
- Cong XJ, Yin G, Shen Y. Marginal Analysis of Correlated Failure Time Data with Informative Cluster Sizes. Biometrics 63(3):663-672, 2007. e-Pub 2007. PMID: 17825000.
- Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104(10):3967-72, 2007. e-Pub 2007. PMID: 17360461.
- Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma 47(3):417-23, 2006. e-Pub 2006. PMID: 16396764.
- Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295:299-305, 2006. e-Pub 2006. PMID: 16418465.
- Zeng D, Cai J, Shen Y. Semiparameteric additive risks model for interval-censored data. Statistica Sinica 16:287-95, 2006. e-Pub 2006.
- Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12:5442-7, 2006. e-Pub 2006. PMID: 17000678.
- Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics 61(4):992-9, 2005. e-Pub 2005. PMID: 16401272.
- Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97(16):1195-203, 2005. e-Pub 2005. PMID: 16106024.
- Yin G, Shen Y. Self-designing trial combined with classical group sequential monitoring. J Biopharm Stat 15:667-75, 2005. e-Pub 2005. PMID: 16022171.
- Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 6:604-14, 2005. e-Pub 2005. PMID: 15860542.
- Shen Y, Parmigiani G. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev 14:529-32, 2005. e-Pub 2005. PMID: 15734983.
- Handy BC, Shen Y. Evaluation of potassium values in a cancer patient population. LabMedicine 36:1-3, 2005. e-Pub 2005.
- Cong XJ, Shen Y, Miller AB. Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. Stat Med 24:3123-38, 2005. e-Pub 2005. PMID: 15977269.
- Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810-6, 2005. e-Pub 2005. PMID: 15713770.
- Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 61(2):343-54, 2005. e-Pub 2005. PMID: 16011680.
- Cheng Y, Shen Y. Bayesian Adaptive Designs for Clinical Trials. Biometrika 92:633-646, 2005. e-Pub 2005.
- Yin G, Shen Y. Adaptive design and estimation in randomized clinical trials with correlated observations. Biometrics 61:362-9, 2005. e-Pub 2005. PMID: 16011682.
- Shen Y, Berry DA. Re: Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials (multiple letters). Journal of the National Cancer Institute 97(24):1853-1854, 2005. e-Pub 2005.
- Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10:33-42, 2004. e-Pub 2004. PMID: 14734449.
- Cheng Y, Shen Y. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials. Biometrics 60:910-8, 2004. e-Pub 2004. PMID: 15606411.
- Shen Y, Cai J. Sample size re-estimate for clinical trials with censored survival data. J Am Stat Assoc 98:418-426, 2003. e-Pub 2003.
- Shen Y, Wu D, Zelen M. Testing the independence of two diagnostic tests. Biometrics 57:1009-17, 2001. e-Pub 2001. PMID: 11764239.
- Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 19:3490-9, 2001. e-Pub 2001. PMID: 11481355.
- Van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Jr, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92:2837-44, 2001. e-Pub 2001. PMID: 11753957.
- Shen Y, Cai J. Maximum of the weighted Kaplan-Meier tests with application to cancer prevention and screening trials. Biometrics 57:837-43, 2001. e-Pub 2001. PMID: 11550935.
- Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O'Brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma 42:67-73, 2001. e-Pub 2001. PMID: 11699223.
- Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 92:1999-2015, 2001. e-Pub 2001. PMID: 11596013.
- Cai J, Shen Y. Permutation tests for comparing marginal survival functions with clustered failure time data. Stat Med 19:2963-73, 2000. e-Pub 2000. PMID: 11042626.
- Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 95:72-7, 2000. e-Pub 2000. PMID: 10607687.
- Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects. Biometrics 56:213-9, 2000. e-Pub 2000. PMID: 10783798.
- Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics 55:190-7, 1999. e-Pub 1999. PMID: 11318154.
- Shen Y, Zelen M. Estimation procedures for screening programs: Stable and nonstable disease models for multi-modality case finding. Biometrika 86:503-515, 1999. e-Pub 1999.
- Shen Y, Cheng SC. Confidence bands for cumulative incidence curves under the additive risk model. Biometrics 55:1093-100, 1999. e-Pub 1999. PMID: 11315053.
- Shen Y, Fleming TR. Assessing effects on long-term survival after early termination of randomized trials. Lifetime Data Anal 5:55-66, 1999. e-Pub 1999. PMID: 10214002.
- Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med 17:999-1015, 1998. e-Pub 1998. PMID: 9612887.
- Shen Y, Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data. J R Stat Soc Ser B 59:269-280, 1997. e-Pub 1997.
- Shen Y, Fleming TR. Large sample properties for some survival estimators in heterogeneous samples. J Stat Plan Inference 60:123-138, 1997. e-Pub 1997.
- Etzioni R, Shen Y. Estimating asymptomatic duration in cancer: the AIDS connection. Stat Med 16:627-44, 1997. e-Pub 1997. PMID: 9131752.
- Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Research 56:3870-4, 1996. e-Pub 1996. PMID: 8752148.
- Etzioni R, Shen Y, Petteway JC, Brawer MK. Age-specific prostate-specific antigen: a reassessment. Prostate Suppl 7:70-7, 1996. e-Pub 1996. PMID: 8950367.
Editorials
- Bedrosian I, Shen Y. Breast conserving therapy or mastectomy: a done deal or one worth returning to?. J Comp Eff Res 4(3):1-3, 2015. PMID: 25959556.
Abstracts
- Ueno NT, Tahara RK, Reuben JM, Gao H, Saigal B, Ujii T, Lucci A, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis, 2018. e-Pub 2018.
- Shen Y. Margins < 2 mm for patients with ductal carcinoma in situ and contraindication for breast conservation with radiotherapy, 2017. e-Pub 2017.
- Shen Y, Dong W, Xu Y, Shih YT. DO ADVANCES IN BREAST CANCER TREATMENT RENDER SCREENING MAMMOGRAPHY, 2017. e-Pub 2017.
- Shen Y. USE OF RELATIVE RISK RATIOS TO PRESENT UNCERTAINTY IN MICROSIMULATION MODELS WITH MULTIPLE COMPARATORS: AN APPLICATION TO BREAST CANCER SCREENING STRATEGIES, 2017. e-Pub 2017.
- Shen Y. Estimation of cancer natural history and overdiagnosis from cancer screening trials, 2017. e-Pub 2017.
- Weiss A, Chi CK, Shen Y, Shaitelman SF, Garvey PB, Bedrosian I, Babiera GV. What factors are associated with reconstruction in the metastatic breast cancer patient? Results from the National Cancer Database, 2017. e-Pub 2017.
- Moreno, A, Lin HY, Bedrosian I, Smith B, Babiera G, Stauder M, Buchholz T, Woodward W, Shen Y, Shaitelman S. Effect of adjuvant radiation therapy with or without regional node irradiation on overall survival in patients with high-risk invasive breast cancer: A National Cancer Database Analysis, 2016. e-Pub 2016.
- Menen RS, Lin HY, Shen Y, Shaitelman S, Bedrosian I, Woodward W, Ueno N, Valero V, Babiera G. Resection of the primary tumor substantially improves median overall survival in patients with Stage IV metastatic inflammatory breast cancer, 2016. e-Pub 2016.
- Menen RS, Lin HY, Shen Y, Shaitelman S, Bedrosian I, Woodward W, Ueno N, Valero V, Babiera G. Resection of the primary tumor substantially improves median overall survival in patients with Stage IV metastatic inflammatory breast cancer. Proceedings of the Society of Surgical Oncology 69th Annual Cancer Symposium, Boston, MA March 2-5, 2016 (Poster Presentation, Abstract #2373536), 2016. e-Pub 2016.
- Fujii T; Kogawa T; Dong W; Litton J; Moulder S; Tripathy D; Hunt K; Iwamoto T; Pusztai L; Lim B; Shen Y; Ueno N. New threshold of ER positivity in early stage HER2- breast cancer. e-Pub 2016.
- Barcenas C; Sinha A; Raghavendra A; Syed M; Hsu L; Patangan M; Chavez-Mac Gregor M; Shen Y; Giordano S; Ueno N; Valero V; Tripathy D. Outcomes after chemotherapy in early-stage breast >cancer (EBC) patients who underwent a 21-gene expression assay. e-Pub 2016.
- Brewster AM, Peterson SK, Bedrosian I, Dong W, Cantor SB, Volk RJ, DuPont H, Shen Y, Parker P. Psychosocial Predictors of Decision Making for Contralateral Prophylactic Mastectomy. e-Pub 2016.
- Tina Shih Y; Dong W; Xu Y; Shen Y. Assessing the Cost-Effectiveness of the American Cancer Society’s Updated Breast Cancer Screening Guideline for Women at Average Risk. e-Pub 2016.
- Lin H, Babiera G, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno NT, Shen Y. Factors Influencing Treatment of Inflammatory Breast Center in The United States, 2015. e-Pub 2015.
- Colfry J, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Patterns of Axillary Surgery in DCIS Patients Within the US National Cancer Database, 2015. e-Pub 2015.
- Colfry J, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Patterns of Axillary Surgery in DCIS Patients Within the US National Cancer Database. Proceedings of the American Society of Breast Surgeons 16th Annual Meeting in Orlando, FL. April 29 - May 3, 2015 (Poster Presentation, Abstract #2145010). JAMA Surgery, 2015. e-Pub 2015.
- Colfry AJ, Lin H, Shen Y, Kuerer HM, Shaitelman S, Babiera GV, Bedrosian I. Factors Associated with DCIS diagnosis: A Population Based Review of the National Cancer Database, 2015. e-Pub 2015.
- Loveland-Jones C, Shaitelman S, Lin H, Shen Y, Bedrosian I, Kuerer HM, Babiera GV. Disparities in the Use of Post-Mastectomy Radiation Therapy for Inflammatory Breast Cancer, 2015. e-Pub 2015.
- Loveland-Jones C, Shaitelman S, Lin H, Shen Y, Bedrosian I, Kuerer HM, Babiera GV. Disparities in the Use of Post-Mastectomy Radiation Therapy for Inflammatory Breast Cancer. Proceedings of the Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, TX March 25-28, 2015 (Poster Presentation, Abstract # 2086390), 2015. e-Pub 2015.
- Colfry AJ, Lin H, Shen Y, Kuerer HM, Shaitelman S, Babiera GV, Bedrosian I. Factors Associated with DCIS diagnosis: A Population Based Review of the National Cancer Database. Proceedings of the Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, TX March 25-28, 2015 (Poster Presentation, Abstract # 2092577). Jama Surgery, 2015. e-Pub 2015.
- Parker C, Lin HY, Shen Y, Li L, Lautner MA, Kuerer HM, Shaitelman SF, Babiera G, Cancer Center IBTUOTMA, Houston, Oncology Group TRT, Cancer Center TUOTMA, Houston, TX. Effect of hormone receptor status and local treatment on overall survival for early-stage breast cancer, 2014. e-Pub 2014.
- Cupp JA, Liu DD, Shen Y, Ueno NT, Alvarez RH, Chavez-Macgregor M, Woodward W, Kogawa T, Babiera G. Factors Influencing Survival in Inflammatory Breast Cancer, 2014. e-Pub 2014.
- Lautner MA, Lin H, Shen Y, Parker C, Kuerer HM, Shaitelman S, Babiera G, Bedrosian I. Disparities in utilization of breast-conserving therapy among breast cancer patients, 2014. e-Pub 2014.
- Lautner MA, Lin H, Shen Y, Parker C, Kuerer HM, Shaitelman S, Babiera G, Bedrosian I. Disparities in utilization of breast-conserving therapy among breast cancer patients. Proceedings of the 2014 ASCO Breast Cancer Symposium, San Francisco CA September 4-6, 2014 (Abstract # 104), 2014. e-Pub 2014.
- Reuth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of Tri-Modality Treatment Impacts Survival for Patients with Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends from The National Cancer Database, 2014. e-Pub 2014.
- Lautner M, Parker C, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. National Trends in Mastectomy Rates from 1998 to 2010, 2014. e-Pub 2014.
- Lautner M, Parker C, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. National Trends in Mastectomy Rates from 1998 to 2010. Proceedings of the Society of Surgical Oncology 67th Annual Cancer Symposium, Phoenix, AZ March 12-15, 2014 (Poster Session, Abstract #1850921), 2014. e-Pub 2014.
- Reuth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of Tri-Modality Treatment Impacts Survival for Patients with Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends from The National Cancer Database. Proceedings of the Society of Surgical Oncology 67th Annual Cancer Symposium, Phoenix, AZ March 12-15, 2014 (Poster Session, Abstract # 1837679), 2014. e-Pub 2014.
- Shaitelman SF, Lin H, Shen Y, Bedrosian I, Bloom ES, Babiera G. Utilization of Accelerated Partial Breast Irradiation (APBI) and Guidline Concordance: Analysis of the National Cancer Database, 2013. e-Pub 2013.
- Shaitelman SF, Lin H, Shen Y, Bedrosian I, Bloom ES, Babiera G. Utilization of Accelerated Partial Breast Irradiation (APBI) and Guidline Concordance: Analysis of the National Cancer Database. Proceedings of the ASCO 2013 Breast Cancer Symposium, San Francisco, CA September 7-9, 2013 (Abstract # 119569), 2013. e-Pub 2013.
- Siefker-Radtke, O;Wen A, Shen S, Stigall Y, McConkey K, Millikan DJ, Randall E. A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC), 2013. e-Pub 2013.
- Hoffman, Niu K, JG ; Shen JG, Y ; Jiang Y, J ; Shah J, JB ; Smith JB, GL ; Davis GL, JW ; Kim JW, J ; Volk J, R ; Kuban R, Giordano D, Smith S, BD. Does the diagnosing urologist influence choice of initial active treatment versus observation in older men with favorable prostate cancer?, 2013. e-Pub 2013.
- Siefker-Radtke, Wen A, Shen S, Stigall Y, McConkey K, DJ;Millikan, RE. A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC), 2013. e-Pub 2013.
- Shen, Zhong Y, Y ; Lai Y, Wang C, Shaw T, C. Cone Beam Breast CT with a High Resolution Flat Panel Detector-Improvement of Calcification Visibility, 2012. e-Pub 2012.
- Lai, Shen C, Zhong Y, Whitman Y, Yang G, W ; Wang W, Shaw T, C. Extraction and Insertion of Tumor Masses in Cone Beam Breast CT Images, 2012. e-Pub 2012.
- Meng, Z (Meng Z, Liu Z, L (Liu L, Shen L, Y (Shen Y, Yang Y, P (Yang P, Cohen P, L (Cohen L, Huo L, Y (Huo Y, Zhao Y, Q (Zhao Q, Ng Q, CS (Ng CS, C S); Chang C, DZ (Chang DZ, D Z); Garrett D, CR (Garrett CR, C R) C. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC), 2011. e-Pub 2011.
- Meng, Z;Liu, L ; Shen L, Yang Y, P (Yang P, Cohen P, L (Cohen L, Huo L, Y (Huo Y, Zhao Y, Q ; Ng Q, CS ; Chang CS, Garrett D, CR. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC), 2011. e-Pub 2011.
- Shen, Yu. Inference of Tamoxifen’s Effects on Prevention of Breast Cancer, 2009. e-Pub 2009.
- Shen, Yu. Semi-parametric Regression Models for Length-biased and Right-censored Failure Time Data, 2008. e-Pub 2008.
- Feng, W, Shen L, Rosen DG, Liu J, Shen Y, Hunt KK, Orlandi R, Bast Jr RC, J-PJ I, Yu Y. CpG island methylator phenotype (CIMP): a novel biomarker to predict new therapy for breast cancer, 2006. e-Pub 2006.
- Shen Y. Adaptive designs in clinical trials, 2006. e-Pub 2006.
- Harris L, Tuziak T, De La Cerda J, Rosen D, Xiao L, Shen Y, Sabichi A, Czerniak B, Grossman HB. Tissue microarray analysis of connexin-26 and Drg-1 in urinary bladder cancer, 2006. e-Pub 2006.
- Shen Y. Bayesian Adaptive Designs for Clinical Trials, 2005. e-Pub 2005.
- Shen Y, Cai J. Sample size re-estimation for clinical trials with censored survival data, 2005. e-Pub 2005.
- Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening, 2005. e-Pub 2005.
- Cheng Y, Shen Y. Bayesian Adaptive designs for clinical trials, 2004. e-Pub 2004.
- Jacobsohn KM, Kamat AM, Shen Y, Troncoso P, Wen S, Babaian RJ. Validation of selection criteria used for predicting extraprostatic cancer extension in patients undergoing nerve sparing radical prostatectomy, 2004. e-Pub 2004.
- Madsen LT, Huber NJ, Wen S, Shen Y, Babaian RJ, Wood CG, Wang R. Penile rehabilitation after fadical prostatectomy: A compliance study, 2004. e-Pub 2004.
- Harris L, De La Cerda J, Czerniak B, Yang Y, Shen Y, Sabichi A, Grossman HB. Tissue microarray analysis of pAKt, PTEN and L-plastin in urinary bladder cancer, 2004. e-Pub 2004.
- Shen, Parmigiani Y, Giovanni. Optimization of Breast Cancer Screening, 2003. e-Pub 2003.
- Shen, Cheng Y, Su-chun. Prediction of cumulative incidence function under additive risk model, 2003. e-Pub 2003.
- Shen Y, Thall P. Parametric likelihoods for times to multiple competing risk non-fatal events and death, 2003. e-Pub 2003.
- Shen Y, Cheng Y. Estimation of a parameter and its exact confidence interval following an adaptive design, 2003. e-Pub 2003.
- Gee J, Montoya R, De LaCerda J, Wen S, Shen Y, Khaled H, Sabichi AL, Grossman HB. COX-2 is Preferentially Expressed in High-Grade Invasive Transitional Cell Carcinoma of the Bladder, 2002. e-Pub 2002.
- Dinney C, Millikan R, Slaton J, Shen Y, Williams D, Logothetis C. Prognostic Significance of Expressiion of Genes Related to Invasion and Metastasis in Locally Advanced Bladder Cancer Treated with Chemotherapy and Surgery, 2002. e-Pub 2002.
- Shen Y. Statistical inference for self-designing clinical trials, 2001. e-Pub 2001.
- Shen Y. Early Detection for Breast Cancer: How Much can Clinical Breast Examinations Add to Mammography?, 2001. e-Pub 2001.
- Thomas M, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, Davis J, Estey E. Comparison of Fludarabine-containing Salvage Chemotherapy Regimens for Relapsed/Refractory Acute Myelogenous Leukemia (AML), 2001. e-Pub 2001.
- Beran, M, Shen Y, Kantarjian K, Despa S, Estey E. High dose (HD) chemotherapy in high risk (HR) myelodisplastic syndrome (MDS): Covariate adjusted comparison of five regimens, 2000. e-Pub 2000.
- Shen Y, Zelen M. Estimations of screening sensitivity and sojourn time distributions. Biometrika, 2000. e-Pub 2000.
- Shen Y, Fisher L. Sample-size re-estimate in clinical trials with a one-sided hypothesis, 1999. e-Pub 1999.
- Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis, 1998. e-Pub 1998.
- Shen Y, Thall, PF. Parametric likelihoods for times to multiple competing risk non-fatal events and death, 1997. e-Pub 1997.
- Y Shen Y, TR Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data(Ser B 59:269-280,), 1997. e-Pub 1997.
- Shen Y, Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data. J R Stat Soc Ser B(Ser B 59:269-280,), 1997. e-Pub 1997.
- Sinicrope F, Roddey G, Stephens L, Meyn T, Glober G, Shen Y, Pazdur R. Evaluation of bcl-2 and p53 oncogenes and apoptotic rates as predictors of chemotherapy response in colorectal cancer, 1996. e-Pub 1996.
- Sinicrope F, Roddey G, McDonnell T, Shen Y, Stephens L. Progressive increase in apoptotic rates during colorectal tumor progression 110:A595, 1996. e-Pub 1996.
- Seong D, Thall P, Kantarjian H, Talpaz M, O'Brien S, Swantkowski J, Rios M, Xu J, Shen Y, Zimmerman S, Glassman A, Ramagli L, Robinson J, Keating M, Freireich EJ, Champlin R, Siciliano M. A comparison of the sensitivity of interphases FISH on blood and hypermetaphase FISH on bone marrow for the presence of the Ph chromosome in CML, 1996. e-Pub 1996.
- Roddey G, Stephens L, Zhang W, Sellin J, Shen Y, Sinicrope F. Expression of p21 (waf1) and p53 genes during human colorectal tumorigenesis: association with apoptosis, 1996. e-Pub 1996.
- Shen Y Fleming T. Mean survival estimator, with applications for two-sample test, 1995. e-Pub 1995.
- HM Kuerer HM, GM Rauch GM, S Krishnamurthy S, EJ Diego EJ, WT Yang WT, Shen Y, Lin H, Lucci A, DL Ramirez DL, TW Moseley TW, JA Mouabbi JA, Boughey JC, SF Shaitelman SF, White RL, KH Hunt KH, MP Mitchell MP, MT Teshome MT, HM Johnson HM, BD Smith BD, Valero AV. Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial.
Book Chapters
- Singh P, Shen Y, Hunt K. Trial Design: Overview of Study Designs. In: Clinical Trials. Springer International Publishing, 37-45, 2020.
- Shen Y, Parmigianni G. Optimization of breast cancer screening strategies. In: Probability, Statistics and Modeling in Public Health. Springer Science and Business Media, Inc, 405-420, 2006.
- Grossman BH, Sabichi AL, Shen Y. Bladder Cancer: Clinical strategies for cancer chemoprevention. In: Cancer Chemoprevention: Strategies for Cancer Chemoprevention, 315-322, 2005.
Patient Reviews
CV information above last modified September 23, 2026